| 9/30/2022 | 10/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this document is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/01/2022, unless otherwise noted.
For more information related to these services, please refer to specific policies when applicable.
| 0.1 | | 10/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | 76979fc4-70a0-4da0-9763-83d64cf93cd5 |
| 9/27/2022 | Coverage of the COVID-19 Vaccination for Independence Commercial Members (Retroactively effective to August 31, 2022, Issued September 27, 2022) | This communication provides notice regarding information and procedure codes related to the coverage of SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) vaccines and administration of the vaccines that have been granted FDA approval and/or have received an Emergency Use Authorization. Coverage of SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) vaccines granted an EUA shall remain in effect during the applicable EUA declaration, unless the specific EUA for a SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) vaccine has been terminated and/or revoked.
| 0.1 | | Coverage of the COVID-19 Vaccination for Independence Commercial Members (Retroactively effective to August 31, 2022, Issued September 27, 2022) | 1673d146-1dca-494c-bea1-b98f573ae7e0 |
| 9/13/2022 | Expanded Coverage of Pneumococcal 15-valent Conjugate Vaccine for Independence Commercial Members | The purpose of this document is to provide notice regarding the expanded coverage of pneumococcal 15-valent conjugate vaccine for our Independence Commercial members.
| 0.1 | | Expanded Coverage of Pneumococcal 15-valent Conjugate Vaccine for Independence Commercial Members | ab42ab27-eec7-4989-a467-0f507eecc763 |
| 8/24/2022 | Laboratory Testing, Vaccination, and Treatment for Monkeypox for Independence Commercial Members | The purpose of this document is to communicate the Company's coverage positions for laboratory testing, vaccination, and treatment for monkeypox.
| 0.1 | | Laboratory Testing, Vaccination, and Treatment for Monkeypox for Independence Commercial Members | c895bc5e-9105-4155-92c6-5a586f46dd8f |
| 6/29/2022 | 07/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this document is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 07/01/2022, unless otherwise noted.
For more information related to these services, please refer to specific policies when applicable. | 0 | | 07/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | 7ecadee4-3722-4789-8ebe-7f88897f0396 |
| 6/14/2022 | Preventive Coverage of Colonoscopy Following a Positive Non-invasive Stool-based Screening Test or Direct Visualization Test for Independence Commercial Members | The purpose of this communication is to convey our current coverage position regarding coverage of a screening colonoscopy following a positive non-invasive stool-based screening test or direct visualization test for Independence Commercial members.
| 0.1 | | Preventive Coverage of Colonoscopy Following a Positive Non-invasive Stool-based Screening Test or Direct Visualization Test for Independence Commercial Members | 8e53383e-514d-4558-8868-d69787ca978a |
| 5/31/2022 | Preventive Coverage of FDA-Approved Contraceptive Mobile Applications for Independence Commercial Members | The purpose of this communication is to provide notice regarding the preventive coverage of FDA-approved contraceptive mobile applications for Independence Commercial members effective June 1, 2022.
| 0.1 | | Preventive Coverage of FDA-Approved Contraceptive Mobile Applications for Independence Commercial Members | a9a84ad3-aaa7-45ce-b785-63633b8906bb |
| 3/31/2022 | 04/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this document is to communicate Medicare Advantage Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 04/01/2022, unless otherwise noted.
For more information related to these services, please refer to specific policies when applicable.
| 0.1 | | 04/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | 00fd5da3-c5a3-4c49-adf1-5405e7136e9a |
| 3/7/2022 | Preventive Coverage of Recombinant zoster vaccine (Shingrix), 15-Valent Pneumococcal Conjugate Vaccine, and 20-Valent Pneumococcal Conjugate Vaccine for Independence Commercial Members | The purpose of this communication is to provide notice regarding the expanded preventive coverage criteria for recombinant zoster vaccine (Shingrix), 15-Valent Pneumococcal Conjugate Vaccine, and 20-Valent Pneumococcal Conjugate Vaccine for Independence Commercial members effective January 21, 2022.
| 0.1 | | Preventive Coverage of Recombinant zoster vaccine (Shingrix), 15-Valent Pneumococcal Conjugate Vaccine, and 20-Valent Pneumococcal Conjugate Vaccine for Independence Commercial Members | dd4ceef2-2beb-45cd-9523-7be482ca7a88 |
| 2/18/2022 | Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Commercial Members (Updated February 18, 2022) | The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence commercial members.
| 0.1 | | Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Commercial Members (Updated February 18, 2022) | b7b199d0-3bed-420f-a82b-947fc82bf51f |
| 1/24/2022 | Extension of Coverage for Immune Prophylaxis for Respiratory Syncytial Virus (RSV) with palivizumab (Synagis) | The purpose of this communication is to convey notification of coverage of additional doses for palivizumab (Synagis) for the expanded 2021-2022 RSV season.
| 0.1 | | Extension of Coverage for Immune Prophylaxis for Respiratory Syncytial Virus (RSV) with palivizumab (Synagis) | 6b3ee8ba-eb0e-4a98-a0bc-b467099d9746 |
| 12/31/2021 | Coverage of Speech Therapy Services Performed Through Telemedicine for Independence Commercial Members (Updated January 1, 2022) | The purpose of this communication is to provide notice regarding coverage for speech therapy services performed through telemedicine for our Independence Commercial members during the coronavirus disease 2019 public health emergency. | 0.1 | | Coverage of Speech Therapy Services Performed Through Telemedicine for Independence Commercial Members (Updated January 1, 2022) | e1cfa675-fd30-49d8-8ebe-5516fbbac4da |
| 12/31/2021 | 1/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products (Updated January 7, 2022) | The intent of this document is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 01/01/2022, unless otherwise noted. | 0.1 | | 1/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products (Updated January 7, 2022) | 5b4a4df3-2ec7-47ba-b80b-226612429235 |
| 10/1/2021 | 10/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/1/2021, unless otherwise noted.
For more information related to these services, please refer to specific policies when applicable. | 0.1 | | 10/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | 490ecf35-0761-440c-b534-a035b758d9eb |
| 4/1/2021 | 4/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 4/1/2021, unless otherwise noted.
| 0.1 | | 4/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | c832c919-e231-49f5-b0dc-09bc2f5e33b7 |
| 1/4/2021 | 1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Products | The intent of this document is to communicate Commercial Product coverage determinations for services identified through the Annual Code Update process.
| 0 | | 1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Products | b976b7b6-ff87-4f04-a559-d2f8805e0586 |
| 10/22/2020 | Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Commercial Members (Updated August 25, 2022) | The purpose of this document is to communicate the Company's coverage position for Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Commercial members. | 0.1 | | Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Commercial Members (Updated August 25, 2022) | 9e5ad975-cd67-45ec-8603-6c3b69aef179 |
| 4/29/2020 | Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-19 (December 15, 2021)
| The purpose of this News Article is to provide advance notice regarding direct supervision requirements for Incident to services performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in response to Coronavirus Disease 2019 (COVID-19). | 1 | | Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-19 (December 15, 2021) | CC0B8A7BBD74419185258558007CCF61 |
